Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants
New EASL guidelines prioritise interferon-free hepatitis C treatment
Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C
Expanded vaccination and treatment could help eliminate hepatitis B worldwide
Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients
Advanced liver damage is common in people with undiagnosed hepatitis C in US survey
Grazoprevir / elbasvir highly effective in previously untreated hepatitis C
Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease
Merck HCV combination achieves 90% cure in advanced cirrhosis
